Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Gilead Sciences
Georgetown University
Mayo Clinic
Big Ten Cancer Research Consortium
AstraZeneca
M.D. Anderson Cancer Center
Roswell Park Cancer Institute
Merck Sharp & Dohme LLC
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Chicago
University of California, Irvine
M.D. Anderson Cancer Center
Massachusetts General Hospital
Mayo Clinic
M.D. Anderson Cancer Center
Case Comprehensive Cancer Center
Merck Sharp & Dohme LLC
Mirati Therapeutics Inc.
Regeneron Pharmaceuticals
Emory University
Chinese University of Hong Kong
Memorial Sloan Kettering Cancer Center
Centre hospitalier de l'Université de Montréal (CHUM)
Henry Ford Health System
Daiichi Sankyo
The Canadian College of Naturopathic Medicine
SWOG Cancer Research Network
Sun Yat-sen University
Sichuan University
University of Iowa
M.D. Anderson Cancer Center
Mayo Clinic
University of Maryland, Baltimore
Integro Theranostics
University of Washington
City of Hope Medical Center
SWOG Cancer Research Network
Shanghai Pulmonary Hospital, Shanghai, China
University of Washington
Jiangsu HengRui Medicine Co., Ltd.
Lantern Pharma Inc.
Shantou University Medical College
University Hospital, Basel, Switzerland
Sun Yat-sen University
Iovance Biotherapeutics, Inc.
Brown University
Weill Medical College of Cornell University
Memorial Sloan Kettering Cancer Center